Data / Drug companies / Incyte Corporation
Incyte Corporation: 20 products in the FDA NDC directory, labeler code 50881
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Incyte Corporation (labeler code 50881) lists 20 products in the FDA National Drug Code Directory, covering 5 finished drugs by generic name. By type: 20 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on June 24, 2026.
The request: Watch Incyte Corporation (FDA labeler code 50881): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50881
- Products in commercial distribution
- 20
- Packages
- 24
- Finished drugs by generic name
- 5
- Prescription products
- 20
- Over the counter products
- 0
- Flagged as original packager
- 15 of 15 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- November 16, 2011
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 14 | 70% |
| Biologics (BLA) | 6 | 30% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 20 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Ruxolitinib | 11 | 1 |
| Axatilimab-csfr | 4 | 1 |
| Pemigatinib | 3 | 1 |
| Tafasitamab-cxix | 1 | 2 |
| Retifanlimab-dlwr | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 8 | 40% |
| Injection | 5 | 25% |
| Tablet, extended release | 5 | 25% |
| Cream | 1 | 5% |
| Injection, powder, lyophilized, for solution | 1 | 5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Kinase Inhibitor | 14 |
| Janus Kinase Inhibitor | 11 |
| Colony Stimulating Factor-1 Receptor Blocker | 4 |
| Programmed Death Receptor-1 Blocking Antibody | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Niktimvo | 50881-047 | Injection | Biologics (BLA) | June 24, 2026 |
| Niktimvo | 50881-036 | Injection | Biologics (BLA) | June 24, 2026 |
| Jakafi xr | 50881-055 | Tablet, extended release | New drug applications (NDA) | May 1, 2026 |
| Jakafi xr | 50881-044 | Tablet, extended release | New drug applications (NDA) | May 1, 2026 |
| Jakafi xr | 50881-033 | Tablet, extended release | New drug applications (NDA) | May 1, 2026 |
| Jakafi xr | 50881-022 | Tablet, extended release | New drug applications (NDA) | May 1, 2026 |
| Jakafi xr | 50881-011 | Tablet, extended release | New drug applications (NDA) | May 1, 2026 |
| Niktimvo | 50881-034 | Injection | Biologics (BLA) | January 15, 2025 |
| Niktimvo | 50881-023 | Injection | Biologics (BLA) | January 15, 2025 |
| Zynyz | 50881-006 | Injection | Biologics (BLA) | March 22, 2023 |
| Opzelura | 50881-007 | Cream | New drug applications (NDA) | September 21, 2021 |
| Monjuvi | 50881-013 | Injection, powder, lyophilized, for solution | Biologics (BLA) | August 5, 2020 |
| Pemazyre | 50881-028 | Tablet | New drug applications (NDA) | April 17, 2020 |
| Pemazyre | 50881-027 | Tablet | New drug applications (NDA) | April 17, 2020 |
| Pemazyre | 50881-026 | Tablet | New drug applications (NDA) | April 17, 2020 |
| Jakafi | 50881-025 | Tablet | New drug applications (NDA) | November 16, 2011 |
| Jakafi | 50881-020 | Tablet | New drug applications (NDA) | November 16, 2011 |
| Jakafi | 50881-015 | Tablet | New drug applications (NDA) | November 16, 2011 |
| Jakafi | 50881-010 | Tablet | New drug applications (NDA) | November 16, 2011 |
| Jakafi | 50881-005 | Tablet | New drug applications (NDA) | November 16, 2011 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.